The Hepatotoxicity of Intravenous Aureomycin

Publisher Website
Google Scholar
Abstract
THIS report deals with hyperbilirubinemia developing during the intravenous administration of aureomycin in a series of 39 patients. To determine the relation of intravenously administered therapeutic doses of aureomycin to this disorder the effect of the drug on normal liver function was studied in 20 selected patients with no evidence of cardiovascular, renal, hepatic or biliary-tract disease. Each patient received aureomycin (500 mg. of the hydrochloride buffered with sodium glycinate, dissolved in 500 cc. of isotonic sodium chloride) intravenously twice a day for three consecutive days. Serum bilirubin§ and urinary urobilinogen§ excretion were determined in all 20 patients. Serum bilirubin . . .